Retractable shifts production onshore as tariffs and investment losses squeeze profits

Retractable Technologies, Inc. (NYSE: RVP) - Quick read on what's happening inside the company

Snapshot - the situation inside
Retractable is shifting production onshore to blunt steep China tariffs, cutting staff and converting equipment under its BARDA/TIA program while using investment sales to fund operations. Revenue is up year-over-year but profitability is pressured by tariffs, inventory write‑downs and a large unrealized investment loss.

Key facts & statistics (as reported - Q2 / YTD)

- Sales, net: $10,445,733 (three months ended 6/30/2025) vs $6,029,364 a year earlier; $18,740,906 (six months) vs $13,628,727.
- Gross profit (loss): $(107,090) Q2; $(109,001) YTD (vs Q2 $(419,924) and YTD $1,481,005 prior year).
- Loss from operations: $(5,130,837) Q2; $(9,807,591) YTD.
- Net loss: $(87,471) Q2; $(10,588,187) YTD. Net loss applicable to common shareholders: $(145,082) Q2; $(10,703,409) YTD.
- Basic/diluted loss per share (basic): $(0.00) Q2; $(0.36) YTD. Weighted common shares: 29,937,159.
- Cash and cash equivalents: $3,044,986 (6/30/2025) down from $4,235,388 (12/31/2024).
- Investments (fair value): $30,009,302 (6/30/2025) vs $40,328,308 (12/31/2024). Unrealized loss on investments YTD: $5,600,837.
- Inventories: $20,449,860 (up from $19,189,753). Inventory write‑downs: ~$601k (Q2), ~$617k (YTD).
- Accounts receivable: $8,085,890 (up from $7,786,697).
- Total assets: $147,090,406 (down from $160,724,202). Total liabilities: $70,623,124.
- Other long‑term liabilities (TIA reimbursements): $60,918,499 (6/30/2025).
- Cash used in operations (six months): $(5,209,566). Cash from investing (sale of securities): $5,000,000 proceeds included.
- Tariff impact: ~$561k in Q2 2025; ~$2.1M YTD. Company estimates future tariff rates (management belief): syringes/needles ~130%, other imports ~30% until final trade deal.
- Significant customers: 3 customers accounted for $6.0M (57.2%) of Q2 sales.
- China sourcing: 62% of products in first six months of 2025 came from Chinese manufacturers (was 91% in 2024).
- Deferred tax valuation allowance: $11.3M (6/30/2025), up from $9.1M.

Positives

- Top-line growth: Sales rose materially Y/Y - Q2 sales $10.45M vs $6.03M prior year; YTD sales up to $18.74M.
- Operating discipline: Operating expenses declined (sales & marketing, R&D steady; G&A down Y/Y) and company is executing headcount adjustments to lower workforce costs.
- Strong support from TIA/BARDA program: $2.95M in TIA-related income YTD helps offset some operating shortfalls and funded domestic capacity buildout.
- One‑time litigation settlement: $1.9M received in May 2025 improved cash inflows.
- Liquidity options: Management states adequate means to meet short‑term needs for ≥12 months and can liquidate investments if needed.

Negatives / risks

- Profitability under pressure: Gross loss for the six months and operating losses persist - YTD net loss $(10.6M).
- Investment losses: $5.6M unrealized loss YTD materially increased net loss and reduced investments from $40.3M to $30.0M.
- Tariffs & supply risk: Heavy reliance on Chinese manufacturing (62% of products YTD) and tariffs caused $2.1M YTD expense; uncertainty on final tariff structure remains a material risk.
- Inventory & write‑downs: Inventory increased and the company recorded inventory write‑downs (~$617k YTD) tied to product expirations and mix shifts.
- Customer concentration: 3 customers accounted for ~57% of Q2 sales - concentration risk to revenue.
- Large TIA liability: Other long‑term liabilities tied to TIA remain large ($60.9M) and will be amortized as income over asset life; this creates ongoing reporting complexity and obligations through 2030.
- Deferred tax asset limited: Valuation allowance increased to $11.3M, reducing potential tax shield realization.

Operational changes to watch (near term)

- Execution of domestic manufacturing ramp: management is converting equipment and expects commercial quantities for some domestically produced items in H2 2025 - this should lower future tariff exposure but raise labor costs.
- Workforce actions: Recent reductions (announced July 23, 2025) target manufacturing/support costs - monitor realized savings vs lost capacity.
- Investment portfolio moves: further sales of securities may fund operations but lock in gains/losses and shrink liquidity buffer.
- Tariff/trade outcomes: any final U.S.-China tariff agreement will materially affect margins and sourcing strategy.

Bottom line
Retractable (NYSE: RVP) is growing revenue but not yet translating that growth into sustainable profits. The company is executing a sensible playbook - shift production onshore, use TIA-funded capacity, cut costs - but faces near-term headwinds from tariffs, inventory adjustments and investment mark‑to‑market losses. Key catalysts that could improve the picture: successful domestic ramp, clearer tariff resolution, or recovery in the company's investment portfolio. Key near‑term risks: sustained tariffs, customer concentration, and continued unrealized investment volatility.